SLC9A2 and neoplasm: Furthermore, our research identifies the JAK inhibitor Ruxolitinib as a promising agent that can inhibit tumor metastasis at early stages and synergize with immunotherapy in advanced stages, particularly benefiting patients with low SLC9A2 expression.